Document:

Master Services Agreement

 Exhibit 4.3 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 Dated 01 April 2011 

PRIMA BIOMED LTD 
 (ABN 90 009 237 889) 
 And 

CELL THERAPIES PTY LTD 
 (ABN 15 100 285 916) 
  

 
 MASTER
SERVICES AGREEMENT 
  
  

 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
			
	1.	  	DEFINITIONS, INTERPRETATION	  	 	2	  
			
	2.	  	APPOINTMENT OF CT	  	 	5	  
			
	3.	  	TERM OF THE AGREEMENT	  	 	5	  
			
	4.	  	PERFORMANCE OF THE SERVICES	  	 	5	  
			
	5.	  	OBLIGATIONS OF PRIMA	  	 	7	  
			
	6.	  	INVOICING AND PAYMENT	  	 	7	  
			
	7.	  	APPOINTMENT OF AUTHORISED REPRESENTATIVES & PERIODIC REVIEW	  	 	8	  
			
	8.	  	CONFIDENTIALITY / INFORMATION	  	 	8	  
			
	9.	  	PRIVACY	  	 	9	  
			
	10.	  	SERVICE RESULTS	  	 	10	  
			
	11.	  	INSURANCE	  	 	11	  
			
	12.	  	INDEMNITY	  	 	11	  
			
	13.	  	REPRESENTATIONS AND WARRANTIES	  	 	12	  
			
	14.	  	TERMINATION OR EXTENSION	  	 	13	  
			
	15.	  	ETHICS COMMITTEE APPROVAL AND PATIENT CONSENT	  	 	14	  
			
	16.	  	RELATIONSHIP	  	 	15	  
			
	17.	  	VARIATION	  	 	15	  
			
	18.	  	ASSIGNMENT	  	 	15	  
			
	19.	  	SUBCONTRACTING	  	 	15	  
			
	20.	  	NOTICES TO PRIMA	  	 	15	  
			
	21.	  	NOTICES TO CT	  	 	16	  
			
	22.	  	DISPUTE RESOLUTION	  	 	16	  
			
	23.	  	GOVERNING LAW AND JURISDICTION	  	 	16	  
			
	24.	  	ENTIRE AGREEMENT	  	 	16	  
			
	25.	  	NO WAIVER	  	 	16	  
			
	26.	  	REMEDIES CUMULATIVE	  	 	17	  
			
	27.	  	COUNTERPARTS	  	 	17	  
			
	28.	  	SEVERABILITY OF PROVISIONS	  	 	17	  
			
	29.	  	GST GENERAL PRINCIPLES	  	 	17	  
			
	30.	  	RELEASE OF INFORMATION	  	 	17	  
		
	 SCHEDULE 1
	  	 	1	  
		
	 SCHEDULE 2
	  	 	1	  
		
	 SCHEDULE 3
	  	 	1	  

  
 -i-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 THIS MASTER SERVICES AGREEMENT (“Agreement”) is made 01 April 2011 

BETWEEN 
 Cell Therapies Pty Ltd (ABN 15
100 285 916) of Ground Floor, 10 St Andrews Place, East Melbourne, Victoria 3002 Australia (“CT”) 
 AND 

Prima Biomed Ltd (ABN 90 009 237 889) of 1233 High Street, Armadale, Victoria 3143 Australia (“PRIMA”). 

Each a “Party” and collectively, “Parties” 
 RECITALS 
  

	A.	This agreement replaces all previous agreements and understandings between the Parties. 

 

	B.	PRIMA is in the process of undertaking a series of clinical trials, developing improved manufacturing processes, developing potency assays, negotiating with multiple
regulatory authorities and researching the capabilities and characteristics of its intellectual property related to dendritic cell vaccines. 

  

	C.	CT is a commercial division of the Peter MacCallum Cancer Centre (“Peter Mac”). 

 

	D.	CT conducts all commercial activities involving the staff and facilities of Peter Mac’s Centre for Blood Cell Therapies (CBCT). 

 

	E.	CT has a range of skills and expertise that can be of value to PRIMA. 

  

	F.	CT agrees to provide services as requested by and directed by PRIMA (“Services”), initially described in Schedule 1, and as may change from time to time as
directed by PRIMA’s Authorized Representative, according to the fees and terms described in Schedule 2. 

  

	G.	From time to time, PRIMA may also request, and CT may accept, to provide additional Services, and such Services, fees, and terms will be documented in an additional
Project Contract. Any such Project Contract will be incorporated into this Agreement by reference and made an integral part hereto. Unless specifically stated otherwise in a Project Contact, the general terms and conditions of this Agreement shall
govern any future Project Contract. 

  

	H.	Accordingly, PRIMA wishes to engage CT to provide the Services pursuant to the terms and conditions contained in this Agreement. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 IT IS THEREFORE AGREED AS FOLLOWS 

 

	1.	DEFINITIONS, INTERPRETATION 

  

	1.1	Definitions 

 The
following definitions apply unless the context requires otherwise: 
 “Authorised Representative” means the
authorised contact person for a Party for all purposes connected with this Agreement; 
 “Commencement Date”
means the 1st of April 2011 
 “Confidential Information” means any information whether written, oral or
otherwise relating to the past, present, future or proposed research or business of a Party or a related body corporate of Party including, without limitation: 
  

	 	(a)	all investigations, data, reports, analyses, forms, memoranda, specifications, letters, processes, procedures, research and development information, formulae,
conclusions, methodologies, research plans, project descriptions, business plans and projections, profit and loss statements, management reports, arrangements and agreements with third parties, strategic planning details, business and other systems
retained by the Party; 

  

	 	(b)	any financial information concerning the conduct, development, financing, managing or selling activities of the Party, relating to the Party’s business or
operation; and 

  

	 	(c)	all information and data relating to the operations, dealings, property, assets, technology, activities and services of a Party, including without limitation
Intellectual Property Rights, software, source and object code, trade secrets, confidential know-how, client information and information proprietary to clients, client lists, concepts not reduced to material form, designs, drawings, plans and models

 but does not include information which: 

 

	 	(d)	at the time of the disclosure to the receiving Party, was already in the lawful possession of that Party in written form; 

 

	 	(e)	is in or comes into the public domain otherwise than by disclosure in breach of this Agreement or any other breach of confidentiality; 

 

	 	(f)	is independently developed by the receiving Party; or 

  

	 	(g)	is obtained lawfully by the receiving Party from a third Party otherwise than by disclosure in breach of an obligation of confidentiality. 

“CT Improvements” means any improvements, mutations, enhancements, modifications, adaptations, extensions, developments,
applications of and all other technical advances made to any CT Intellectual Property during the course of CT’s performance of the Services, all of which excludes PRIMA Intellectual Property and PRIMA Improvements. 

  
 2. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “CT Intellectual Property” means all the intellectual property owned or
made available by CT to be used by CT in the performance of the Services, all of which excludes PRIMA Intellectual Property. 

“Delegate” means a deputy authorised to act on behalf of an Authorised Representative; 

“Facilities” means the facilities, including clean rooms, laboratories, and administrative space, provided by CT to PRIMA
as a Service, or in support of Services; 
 “Force Majeure” means an event or cause beyond the reasonable
control of the Party claiming force majeure including, without limitation: 
  

	 	(a)	act of God, lightning, storm, flood, fire, earthquake or explosion, cyclone, tidal wave, landslide, adverse weather conditions; 

 

	 	(b)	strike, lockout or other labour difficulty; 

  

	 	(c)	act of public enemy, war (declared or undeclared), sabotage, blockade, revolution, riot, insurrection, civil commotion, epidemic; 

 

	 	(d)	the effects of any applicable laws, orders, rules or regulations of any government or other competent authority; 

 

	 	(e)	breakage or accident or other damage to machinery or equipment; 

  

	 	(f)	power interruption or failure, to either or both of mainline power transmission or backup/emergency generator, howsoever caused” 

“Insolvency Event” means, in respect of a party: 

 

	 	(g)	the party ceases to carry on its business; or 

  

	 	(h)	the party ceases to be able to pay its debts as they become due; or 

  

	 	(i)	any step is taken to enter into an arrangement between the party and its creditors; or 

 

	 	(j)	any step is taken to appoint a receiver, receiver and manager, a trustee in bankruptcy, a liquidator, a provisional liquidator, an administrator or other like person in
respect of any of the party’s assets. 

 “Intellectual Property Rights” means and includes
all present and future intellectual and industrial property rights conferred by statute, at common law or in equity, including (without limitation): 
  

	 	(a)	any patent rights, inventions, patent, copyright, designs, rights in circuit layouts, plant breeder’s rights, trade marks, brand names, domain names, product
names, trade secret, or know-how and other results of intellectual effort in the scientific, technological, bio-technological, industrial, literary or artistic and commercial fields, whether or not registered or capable of registration;

  
 3. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(b)	any application or right to apply for registration in respect of those rights; 

 

	 	(c)	any registration of any of those rights or any registration of any application referred to in Item (b); and 

 

	 	(d)	all renewals and extensions of these rights. 

 “PRIMA Improvements” means any improvements, mutation, enhancements, modifications, adaptations, extensions, developments, application of and all other technical advances made to any
PRIMA Intellectual Property. 
 “PRIMA Intellectual Property” means all the intellectual property owned or made
available by PRIMA to CT to be used by CT in the performance of the Services, including all Intellectual Property Rights subsisting in the Product. 
 “Personal Information” means information about an identifiable individual; 
 “Privacy Laws” means the Privacy Act 1993; 

“Procedure” means, in respect of any Product, the manufacturing processes and SOP’s specified by PRIMA for its
manufacture or storage; 
 “Product” means CVacTM as developed by PRIMA for the treatment of ovarian cancer
or any other indication to be specified by PRIMA, the output of the Procedure specified by PRIMA. 
 “Repeat”
means to do once again what ever sections of the Procedure that are required to achieve a minimum or acceptable yield. 

“Services” means the services set out in Schedule 1, including any other tasks agreed by the Parties in writing;

 “Services Fees” means all charges specified in Schedule 3; 

“Service Results” means the materials, results, PRIMA Improvements and the deliverables which are created, discovered or
developed as a result of CT’s performance of the Services but not including CT Improvements; 
 “SOP” means
standard operating procedure as utilised in the current Good Manufacturing Practice (cGMP) for human blood and tissue. 

“Term” means the terms of this Agreement as set out in Clause 3; 

 

	1.2	Interpretation 

 Headings
are for convenience only and do not affect interpretation. The following rules apply unless the context requires otherwise. 
  

	 	(a)	The singular includes the plural and conversely. 

  
 4. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(b)	A gender includes all genders. 

  

	 	(c)	If a word or phrase is defined, its other grammatical forms have a corresponding meaning. 

 

	 	(d)	A reference to a person, corporation, trust, partnership, unincorporated body or other entity includes any of them. 

 

	 	(e)	A reference to a clause, paragraph, Item, Annexure or Schedule, is a reference to a clause, paragraph or Item of or an Annexure to or a Schedule to, this Agreement.

  

	 	(f)	A reference to an agreement or document (including, without limitation, a reference to this Agreement) is to the agreement or document as this Agreement or that other
agreement or document. 

  

	 	(g)	A reference to a Party to this Agreement or another agreement or document includes the Party’s successors and permitted substitutes or assigns (and, where
applicable, the Party’s legal personal representatives). 

  

	 	(h)	A reference to legislation or to a provision of legislation includes a modification or re-enactment of it, a legislative provision substituted for it and a regulation
or statutory instrument issued under it. 

  

	 	(i)	A reference to writing includes a facsimile transmission and any means of reproducing words in a tangible and permanently visible form. 

 

	 	(j)	(j) All amounts listed in Schedule 2 are in Australian Dollars. 

  

	2.	APPOINTMENT OF CT 

 PRIMA
engages CT to provide the Services for the Term of this Agreement and CT agrees to carry out the Services for the Term in accordance with this Agreement. 
  

	3.	TERM OF THE AGREEMENT 

This Agreement will commence on the Commencement Date and shall continue in full force and effect for a period of five (5) years from
the Commencement Date and thereafter from year to year until either party gives the other party written notice of its intention to terminate the Agreement on the original period of five (5) years or on the expiration of any one such additional
yearly periods, such notice to be given at least [ * ] prior to such termination unless extended or terminated in accordance with Clause 14. 
  

	4.	PERFORMANCE OF THE SERVICES 

  

	 	(a)	CT must perform the Services in accordance with this Agreement and: 

  

	 	(i)	efficiently, with due care and skill and to the best of its knowledge and expertise; 

  
 5. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(ii)	in a time and manner as reasonably requested by PRIMA’s Authorized Representative, such that these requests are within the scope of this Agreement;

  

	 	(iii)	according to any agreed Procedures for a Product; and 

  

	 	(iv)	in compliance with all applicable laws and regulations. 

  

	 	(b)	CT must ensure that the Facilities are cGMP/cGTP compliant in performing all aspects of the Services. 

 

	 	(c)	Subject to an annual four (4) week plant shut down for maintenance CT shall use its best endeavours to ensure that there is sufficient resource allocation within
the Facilities for the provision of the Services. 

  

	 	(d)	CT is to promptly notify PRIMA’s Authorised Representative in the event that the TGA, or any other competent regulatory authority, inspects or intends to inspect
CT’s Facilities or any aspect of the Services provided to PRIMA. CT shall endeavour to arrange for PRIMA to have a representative present at any such inspection. In any case, CT shall provide PRIMA’s Authorised Representative with copies
of all communications with the TGA or any other competent regulatory authority related to the Services. 

  

	 	(e)	When requested by PRIMA, CT shall furnish to PRIMA a comprehensive written report summarizing the data generated to date and the status of Services.

  

	 	(f)	In performing its obligations under this Agreement, CT agrees to use its reasonable endeavours to avoid infringing the Intellectual Property Rights of any third party.

  

	 	(g)	PRIMA acknowledges and agrees that, although CT agrees to apply the same skills and knowledge to the provision of the Services as it applies to the management of its
own Therapeutic Goods Administration (“TGA”) licence, the TGA is an independent regulatory body outside the control of CT. To the extent that the TGA mandates regulations or guidelines that CT cannot predict or interpret, it cannot give
any warranty or assurance as to its compliance with any such regulations and guidelines. PRIMA further acknowledges that CT is neither qualified nor authorised nor empowered to provide legal advice and no element of its provision of the Services is,
or is to be regarded or interpreted as such. 

  

	 	(h)	PRIMA acknowledges and agrees that some of the Services constitute a research project and that as such no particular result or outcome can be guaranteed.

  

	 	(i)	CT must not: 

  

	 	(i)	incur any liabilities in PRIMA’s name or on its behalf, or pledge its credit without PRIMA’s prior written approval; 

  
 6. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(ii)	have or during the Term accept, any obligations to any person that will or may interfere with the CT’s ability to provide the Services in accordance with this
Agreement, without the prior written approval of PRIMA. 

  

	 	(j)	CT must use its reasonable endeavours to: 

  

	 	(i)	make available its personnel and resources to provide the Services; 

  

	 	(ii)	ensure that its personnel are aware of and will comply with CT’s obligations in providing the Services in accordance with this Agreement; 

In carrying out the Services CT must use its reasonable endeavours to comply with PRIMA’s Quality Policy as described in Schedule 3.

  

	5.	OBLIGATIONS OF PRIMA 

  

	 	(a)	Subject to Schedule 2 and Clause 6, and in consideration for the performance of the Services, PRIMA must pay CT the agreed Service Fees according to agreed terms.

  

	 	(b)	PRIMA is required to declare if there are any genetically modified organisms to be used in the processes involved in any Service. 

 

	 	(c)	PRIMA is required to declare if there is any material of animal origin and its status to be used in the processes involved in any Service. 

 

	 	(d)	PRIMA shall be responsible for the: 

  

	 	(i)	procurement of starting material(s) for the Product and their delivery to the CT facilities; and 

 

	 	(ii)	delivery of the Product from the CT facilities to the hospital or other site at which the Product is intended for administration to a patient. 

 

	6.	INVOICING AND PAYMENT 

  

	 	(a)	Unless otherwise agreed in writing, PRIMA must, within [ * ] of receiving an invoice from CT, pay for all costs and expenses according to Schedule 2 and any future
Project Contract. 

  

	 	(b)	PRIMA will pay correctly rendered invoices to: 

 [ * ] 
  

	 	(c)	PRIMA may withhold payment of any invoiced amount which is in dispute. 

  
 7. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	7.	APPOINTMENT OF AUTHORISED REPRESENTATIVES & PERIODIC REVIEW 

 

	 	(a)	Both PRIMA and CT will appoint one of its staff to be the Authorised Representative of that Party. In the case of PRIMA, the Authorised Representative will be [ * ] or
such other person as advised by PRIMA to CT in writing from time to time. In the case of CT, the Authorised Representative will be [ * ] or such other person as advised by CT to PRIMA in writing from time to time. Each Authorised Representative may
appoint a Delegate by notice in writing to the other party. 

  

	 	(b)	CT and PRIMA must ensure that their Authorised Representatives (or their Delegates) are available for consultation with the other Party as reasonably required by the
other Party and within [ * ] of being requested. 

  

	 	(c)	CT and PRIMA must ensure that their Authorised Representatives (or their Delegates) agree to the form and content of external communications that relate to the
performance of the Services. 

  

	 	(d)	If the Parties’ Authorised Representative decides that the obligations of either Party under the Agreement should be altered, the Parties’ Authorised
Representatives will negotiate in good faith appropriate revision of the Services and to the fees payable to CT under Schedules 1 and 2. 

  

	 	(e)	If the Parties’ Authorised Representatives agree to amendments under this clause, the Parties must amend this Agreement in accordance with Clause 17.

  

	 	(f)	If the Parties’ Authorised Representatives cannot agree in relation to any changes to be made pursuant to this clause, the dispute must be referred to dispute
resolution in accordance with Clause 22 

  

	8.	CONFIDENTIALITY / INFORMATION 

  

	 	(a)	CT must not disclose, and must take reasonable steps to ensure that their Affiliates and CT’s and Peter Mac’s employees, contractors and agents do not
disclose, any Confidential Information of PRIMA to any third party, unless the disclosure is required by law. If disclosure is required by law, CT must immediately provide written notice to PRIMA’s Authorised Representative of the requirement
for the disclosure of the Confidential Information and use its reasonable endeavours to withhold any such disclosure for at least [ * ]. 

  

	 	(b)	CT must: 

  

	 	(i)	use Confidential Information of PRIMA only for the purpose of performing the Services in accordance with this Agreement; 

 

	 	(ii)	take all reasonable steps to secure and keep secure all Confidential Information of PRIMA in its possession or control; 

 

	 	(iii)	not use, modify, reverse engineer or make copies, notes or records of the Confidential Information of PRIMA for any purpose other than for performing the Services in
accordance with this Agreement; 

  
 8. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(iv)	not apply for, register or attempt to register, or authorise or assist any third party to apply for or register, under any statute or otherwise in any country any form
of Intellectual Property Rights relating to or incorporating any Confidential Information of PRIMA, without the prior written approval of PRIMA. 

  

	 	(c)	CT warrants that all relevant employees of CT and Peter Mac have entered into written confidentiality agreements undertaking confidentiality obligations no less onerous
than those of CT under this Agreement. On receipt of a request from PRIMA, CT covenants to provide copies of the confidentiality agreements. 

  

	 	(d)	PRIMA must not disclose, and must take reasonable steps to ensure that their Affiliates, and PRIMA’s and their Affiliates’ employees, contractors and agents
do not disclose, any Confidential Information of CT to any third party, unless the disclosure is required by law or to comply with the rules of any stock exchange on which the securities of PRIMA or an Affiliate may be listed from time to time. If
disclosure is required by law or to comply with the rules of any stock exchange on which the securities of PRIMA or an Affiliate may be listed from time to time, PRIMA must immediately provide written notice to CT’s Authorised Representative of
the requirement for the disclosure of the Confidential Information and use its reasonable endeavours to withhold any such disclosure for at least [ * ]. 

  

	 	(e)	Each Party agrees that any disclosure of another Party’s Confidential Information to any of its employees, consultants, Affiliates, licensees and sub licensees
shall be made only if and to the extent necessary to carry out its rights and responsibilities under this Agreement, and shall be limited to the maximum extent possible consistent with such rights and responsibilities and shall only be made to
persons who are bound by written confidentiality obligations to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement. 

 

	 	(f)	Failure to observe the obligations contained in this Clause 8 is a serious breach and may cause irreparable damage to the relevant Party. In addition to any other
remedies available to the relevant Party for disclosure of Confidential Information, the proprietor of the Confidential Information may require the permanent removal of the person who disclosed the Confidential Information from any activities
associated or connected with this Agreement. 

  

	 	(g)	Clause 8 survives the termination of this Agreement. 

  

	9.	PRIVACY 

 Where PRIMA or
its agent provides Personal Information to CT, CT must comply with the Privacy Laws and; 
  

	 	(a)	to the extent permitted by law, not in any way respond to a request for access to Personal Information except to refer the enquirer to PRIMA and to notify PRIMA of the
request; and 

  
 9. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(b)	CT must: 

  

	 	(i)	only use Personal Information for the purpose of this Agreement and not for its own purpose; 

 

	 	(ii)	only disclose Personal Information if it is necessary for the purpose of this Agreement or with the prior written consent of the PRIMA; and 

 

	 	(iii)	ensure that only authorised personnel have access to Personal Information and that all Personal Information is stored securely and is protected from unauthorised
access, use or disclosure; and 

  

	 	(iv)	destroy all Personal Information once this Agreement has ended. 

  

	10.	SERVICE RESULTS 

  

	 	(a)	Nothing in this Agreement will cause the transfer of any rights in or grant any rights to another Party, other than those rights conferred pursuant to Clause 10(b) and
10(c). 

  

	 	(b)	All Services Results and any Intellectual Property Rights subsisting therein will vest in PRIMA and CT assigns to PRIMA all its current and future, legal and beneficial
right, title and interest in and to Service Results and all of its Intellectual Property Rights subsisting therein, with effect on and from the date of creation of Service Results. 

 

	 	(c)	All CT Improvements and any Intellectual Property Rights subsisting therein will vest in CT and PRIMA assigns to CT all its current and future, legal and beneficial
right, title and interest in and to such Service Results and all of its Intellectual Property Rights, if any, subsisting therein, with effect on and from the date of creation of those Service Results. 

 

	 	(d)	Both Parties will execute all documents and do all things reasonably necessary to give effect to clauses 10(b) and 10(c) and to protect all Intellectual Property Rights
arising as a result of this Agreement. 

  

	 	(e)	CT appoints PRIMA as CT’s attorney to carry out any act or execute any document or instrument to the extent necessary to give effect to the assignment under clause
10(b). 

  

	 	(f)	PRIMA appoints CT as PRIMA’s attorney to carry out any act or execute any document or instrument to the extent necessary to give effect to the assignment under
clause 10(c). 

  

	 	(g)	Both parties agree that they will not and must use reasonable endeavours to ensure that its employees, officers, agents and contractors, do not publish any material or
make any media release in relation to or incorporating the Service Results or the parties’ relationship under this Agreement without the prior written approval of the other party (such approval may be withheld at other party’s absolute
discretion). 

  

  
 10.

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(h)	Neither party may use the other’s name, nor any trade mark or logo of the other party nor of a related body corporate of that party without that party’s prior
written approval. 

  

	 	(i)	Any authorised publication or media release made by CT or PRIMA in accordance with this Agreement must acknowledge the other party’s rights in the Service Results
and contributions to the development of the Service Results. 

  

	 	(j)	Clause 10 survives the termination of this Agreement. 

  

	11.	INSURANCE 

  

	 	(a)	Each party will effect and maintain adequate insurance to cover its activities under this Agreement and to indemnify itself against any loss or damage or liability
which it may suffer or cause or incur. These insurances must include professional indemnity, product liability, third party liability insurance and without limiting the foregoing will include insurance in respect of data loss or corruption.

  

	 	(b)	Each party will, upon the request of the other party, produce evidence of the currency of the above insurance policies. 

 

	 	(c)	Each party will comply with the terms of such insurance policies. 

  

	 	(d)	Each party’s obligations in respect of insurance survive expiration or earlier termination of this Agreement for a period of [ * ] from the date of expiry or early
termination. 

  

	12.	INDEMNITY 

  

	 	(a)	PRIMA indemnifies CT, its officers, employees and agents against any claim or proceedings made, threatened or commenced, and any liability, loss, damage or expense
(including damage to real, personal or intellectual property, data loss or corruption, personal injury including death and legal costs on a full indemnity basis) under statute or common law which CT incurs or suffers as a direct or indirect result
of: 

  

	 	(i)	any breach or non-performance by PRIMA of this Agreement, or warranties contained in this Agreement; 

 

	 	(ii)	any wrongful, wilful or negligent act or omission of PRIMA or any of its employees, agents or contractors; 

 

	 	(iii)	any breach of third party rights including Intellectual Property Rights resulting from CT’s or PRIMA’s or any of their related bodies’ corporate use of
PRIMA’s Intellectual Property or Confidential Information or the Service Results. 

 This indemnity does not
apply to the extent that such loss or damage is caused by the negligence, act or omission of CT or Peter Mac. This indemnity survives the termination of this Agreement indefinitely. 

  
 11.

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(b)	CT indemnifies PRIMA, its officers, employees and agents against any claim or proceedings made, threatened or commenced, and any liability, loss, damage or expense
(including damage to real, personal or intellectual property, data loss or corruption, personal injury including death and legal costs on a full indemnity basis) under statute or common law which PRIMA incurs or suffers as a direct or indirect
result of: 

  

	 	(i)	any breach or non-performance by CT of this Agreement, or warranties contained in this Agreement; 

 

	 	(ii)	any wrongful, wilful or negligent act or omission of CT or any of its employees, agents or contractors 

 

	 	(iii)	any breach of third party rights including Intellectual Property Rights resulting from CT’s or PRIMA’s or any of their related bodies’ corporate use of
CT Intellectual Property or CT Confidential Information. 

 This indemnity does not apply to the extent that such
loss or damage is caused by the negligence, act or omission of PRIMA. This indemnity survives the termination of this Agreement indefinitely. 
  

	13.	REPRESENTATIONS AND WARRANTIES 

  

	 	(a)	PRIMA and CT each represent and warrant as follows: 

  

	 	(i)	Organization. It is a corporation duly organized, validly existing and is in good standing under the laws of its respective jurisdiction, is qualified to do
business and is in good standing as a corporation in each jurisdiction in which the performance of its obligations hereunder requires such qualification and has all requisite power and authority, corporate or otherwise, to conduct its business as
now being conducted, to own, lease and operate its properties and to execute, deliver and perform this Agreement. 

  

	 	(ii)	Authorization. The execution, delivery and performance by it of this Agreement have been duly authorized by all necessary corporate action and do not and will
not (a) require any consent or approval of its stockholders or shareholders or (b) violate any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having
applicability to it or any provision of its charter documents or constitution. 

  

	 	(iii)	Binding Agreement. This Agreement is a legal, valid and binding obligation of it enforceable against it in accordance with its terms and conditions.

  

	 	(iv)	No Inconsistent Obligation. It is not under any obligation to any person, or entity, contractual or otherwise, that is conflicting or inconsistent in any respect
with the terms of this Agreement or that would impede the diligent and complete fulfilment of its obligations. 

  
 12.

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(b)	CT warrants that: 

  

	 	(i)	it (and its personnel) has the expertise, resources (including without limitation financial resources), capacity, experience and ability to perform its obligations
under this Agreement; 

  

	 	(ii)	it has adequate insurance policies and financial resources to sustain any potential liability incurred in relation to this Agreement; 

 

	 	(iii)	it holds and will at all relevant times hold all necessary licences and authorities legally required to perform the Services; 

 

	 	(iv)	the conduct of the Services will be of high quality and provided in a professional manner, with all due care, skill and attention and CT will use its reasonable
endeavours to perform the Services in accordance with industry best practice; and 

  

	 	(v)	it will perform its obligations in a timely and efficient manner. 

  

	 	(c)	Notwithstanding anything else in this Agreement or otherwise, to the fullest extent permitted by law, none of PRIMA or CT will be liable with respect to any subject
matter of this Agreement under any contract, negligence, strict liability or other legal or equitable theory for any indirect, incidental, consequential damages or lost profits. 

 

	14.	TERMINATION OR EXTENSION 

  

	 	(a)	PRIMA may immediately terminate this Agreement by giving written notice to CT if CT: 

 

	 	(i)	commits a breach of any of the provisions of this Agreement which is incapable of being remedied to the reasonable satisfaction of PRIMA; 

 

	 	(ii)	for any reason whatsoever becomes incapable, in the reasonable opinion of PRIMA from performing its obligations under this Agreement; 

 

	 	(iii)	fails to remedy, to the reasonable satisfaction of PRIMA a breach or default of any of the provisions of this Agreement which is, in the opinion of PRIMA capable of
being remedied, within [ * ] of receiving a notice from PRIMA of that breach or default; or 

  

	 	(iv)	is the subject of an Insolvency Event, or 

  

	 	(v)	if the TGA refuses to grant regulatory approval for the Product. 

  

	 	(b)	Notwithstanding any other provision of this Agreement, PRIMA or CT may terminate this Agreement for any reason by giving [ * ] written notice to the other party. If
PRIMA terminates this Agreement and, in doing so, delivers to CT a request to such effect CT shall immediately commence an orderly close down of the project activities and be ready to cease performing the Services at the end of the [ * ] notice
period. 

  
 13.

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(c)	An orderly termination is to include, at PRIMA’s cost, CT transferring the CVacTM manufacturing information to PRIMA’s nominated resource,

  

	 	(d)	PRIMA may request an extension and CT agrees to negotiate in good faith a new Term and revisions of both the Services and the Fees schedules. The Parties agree that
such an extension is to be negotiated at least [ * ] prior to the expiry of the prevailing Term. 

  

	 	(e)	CT may immediately terminate this Agreement by giving written notice to PRIMA if PRIMA 

 

	 	(i)	commits a breach of any of the provisions of this Agreement which is incapable of being remedied to the reasonable satisfaction of CT; 

 

	 	(ii)	fails to remedy, to the reasonable satisfaction of CT a breach or default of any of the provisions of this Agreement which is, in the opinion of CT, capable of being
remedied, within [ * ] of receiving a notice from CT of that breach or default; or 

  

	 	(iii)	is the subject of an Insolvency Event. 

  

	 	(f)	A Party is not liable for any failure or delay in performance of any obligations under this Agreement if all of the following conditions are satisfied:

  

	 	(i)	the failure or delay arose from Force Majeure; and 

  

	 	(ii)	the Party took all reasonable precautions against that Force Majeure and did its best to limit its consequences. This does not require the Party to settle a labour
dispute if, in the Party’s opinion, that is not in its best interests; and 

  

	 	(iii)	the Party gave the other Parties notice of the Force Majeure as soon as practicable after becoming aware of it. 

 

	 	(g)	If the Force Majeure and the resulting failure or delay lasts for more than [ * ] then the Parties will negotiate in good faith to overcome any difficulties associated
with the Force Majeure. 

  

	 	(h)	If the Force Majeure and the resulting failure or delay lasts for more than [ * ] then any Party may terminate the Agreement. 

 

	 	(i)	The Term can be extended if the Parties agree in writing to the terms and conditions to apply to the extension prior to the termination date. 

 

	 	(j)	Despite any other provision of this Agreement, Clauses, 8, 9, 10, 12, 13(b), 13(c), 16, 22, 23 and this Clause 14(j) survives the expiry or termination of this
Agreement. 

  

	15.	ETHICS COMMITTEE APPROVAL AND PATIENT CONSENT 

  

	 	(a)	CT warrants that it will, if necessary, seek approval to provide the Services from the CBCT Ethics Committee, in accordance with the relevant NH&MRC Guidelines.

  
 14.

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(b)	PRIMA warrants that it will ensure that all consent required to be obtained by law from patients in order for CT to perform the Services is obtained. PRIMA will ensure
that copies of such consents are provided to CT within 7 days of CT requesting a copy. 

  

	16.	RELATIONSHIP 

 The
relationship of the Parties is that of independent contractors and nothing in this Agreement constitutes any Party, the employee, partner, agent, fiduciary, representative, trustee or joint venture of the other. No Party is liable for an act or
omission of another Party except to the extent set out in this Agreement. 
  

	17.	VARIATION 

 This Agreement
can only be varied by the Parties in writing and signed by or on behalf of all Parties. 
  

	18.	ASSIGNMENT 

 CT may not
assign any of its rights and obligations under this Agreement without the written consent of PRIMA which consent must not be unreasonably withheld. 
  

	19.	SUBCONTRACTING 

 CT may
not subcontract any of its obligations under this Agreement unless agreed in writing by PRIMA. 
  

	20.	NOTICES TO PRIMA

  

	 	(a)	Any notice required to be given to PRIMA under this Agreement must be in writing and may be served: 

 

	 	(i)	by giving the notice personally to a Director of PRIMA or 

	 	(ii)	by delivering the notice to PRIMA’s registered office. 

 Attn: Managing Director 
 Prima BioMed Limited 

Suite 1, 1233 High Street 
 Armadale Vic 3143 
  

	 	(b)	The notice is served at the time it is given or delivered. 

  

	 	(c)	Electronic transmission of Notices by telefax or email may be used; however, written acknowledgement of receipt must be received by the transmitting Party.

  
 15.

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	21.	NOTICES TO CT 

  

	 	(a)	Any notice required to be given to CT under this Agreement must be in writing and may be served: 

 

	 	(i)	by giving the notice personally to the Managing Director of CT; or 

  

	 	(ii)	by delivering the notice to CT’s registered office at 

 Ground Floor 
 10 St Andrew’s Place 

East Melbourne VIC 3002 
  

	 	(b)	The notice is served at the time it is given or delivered. 

  

	 	(c)	Electronic transmission of Notices by telefax or email may be used however written acknowledgement of receipt must be received by the transmitting Party.

  

	22.	DISPUTE RESOLUTION 

 If a
dispute arises in relation to this Agreement, without restricting either Party from at any time making any application to the Court, either Party may give the other Parties a notice requiring that an attempt be made to resolve the dispute. The
Parties will try to resolve the dispute by the help of Mr Ray Wood and a PRIMA representative nominated by PRIMA. If the dispute is not resolved within [ * ] of the first meeting of Mr Ray Wood and a PRIMA representative, any Party may give the
other a notice requiring that an attempt be made to resolve the dispute with the help of a mediator to be appointed jointly by the Parties. If the Parties do not agree on a mediator within [ * ] after such notice is given, the mediator is to be
appointed by The Australian Commercial Disputes Centre (“ACDC”). The mediation is to be conducted in accordance with the ACDC’s Rules for the Mediation of Commercial Disputes. Each of the Parties must pay an equal share of the fees
and expenses to which the mediator is entitled. 
  

	23.	GOVERNING LAW AND JURISDICTION 

 This document is governed by the laws of Victoria Australia and the Parties submit to the non-exclusive jurisdiction of its courts. The Parties will not object to the exercise of jurisdiction by those
courts, either for forum non conveniens or on any other basis. 
  

	24.	ENTIRE AGREEMENT 

 This
Agreement contains the entire agreement between the Parties with respect to its subject matter and supersedes all prior agreements and understandings between the Parties in connection with it. 

 

	25.	NO WAIVER 

 No failure to
exercise nor any delay in exercising any right, power or remedy by a Party operates as a waiver. A single or partial exercise of any right, power or remedy does not preclude any other or further exercise of that or any other right, power or remedy.
A waiver is not valid or binding on the Party granting that waiver unless made in writing. 

  
 16.

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	26.	REMEDIES CUMULATIVE 

 The
rights, powers and remedies provided to the Parties in this Agreement are in addition to, and do not exclude or limit, any right, power or remedy provided by law or equity. 

 

	27.	COUNTERPARTS 

 This
Agreement may be executed in counterparts. All counterparts together will be taken to constitute one instrument. If each Party executes separate documents, this Agreement takes effect when the Parties exchange executed documents. 

 

	28.	SEVERABILITY OF PROVISIONS 

Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction is ineffective as to that jurisdiction to the
extent of the prohibition or unenforceability. That does not invalidate the remaining provisions of this Agreement nor affect the viability or enforceability of that provision in any other jurisdiction. 

 

	29.	GST GENERAL PRINCIPLES 

  

	 	(a)	The Parties acknowledge that the Service Fees are exclusive of GST. 

  

	 	(b)	If the Australian Tax Office determines GST is applicable then PRIMA will pay any GST assessed to CT. 

 

	30.	RELEASE OF INFORMATION 

The Parties agree that no information about the Services of this Agreement, including its existence, will be released to the Public
without the prior written approval of the Parties which shall not be unreasonably withheld, except as required by law. 

  
 17.

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTED BY THE PARTIES AS AN AGREEMENT 

 

					
	 Signed for and on behalf of

PRIMABIOMED LIMITED
 By its duly
authorised officer
  
 Matthew Lehman

Chief Operating Officer
	  	)  

)
 )

)
 )

)
 )
	  	 /s/ Matthew Lehman
  

 
 Date: April 5, 2011

			
	  
 Signed for and on behalf of

CELL THERAPIES Pty Ltd.
 By its duly
authorised officer
  
 Raymond Wood

Managing Director
	  	)
 )
 )
  
 )

)
 )

)
 )
	  	 /s/ Raymond Wood
  

 
 Date: April 19, 2011

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 SCHEDULE 1 
 THE SERVICES 
 CT agrees to provide to PRIMA the following Facilities, personnel, and other
tasks (together “Services”) under this Agreement: 
  

	 	•	 	 one fully committed and supported cGMP-compliant clean room of a type appropriate for the manufacture of Cvac; 

 

	 	•	 	 cGMP compliant quality system including production and quality personnel; 

 

	 	•	 	 two full-time equivalent Senior Scientists dedicated to PRIMA 

 

	 	•	 	 one full-time equivalent laboratory technician dedicated to PRIMA 

 

	 	•	 	 one part-time laboratory assistant Senior Scientist 

  

	 	•	 	 trained and qualified back-up personnel to replace personnel dedicated to PRIMA in the event of employee termination or leave

  

	 	•	 	 purchase, handling, and storage (including cryostorage) of any starting materials or final product according to Procedures, as reasonably requested by
PRIMA’s Authorized Representative 

 All Services are to be provided in accordance with cGMP, all relevant laws, this
Agreement, and Procedures agreed to between PRIMA and CT. 
 The coordination and scheduling of the use of Facilities and personnel shall be
reasonably directed by PRIMA’s Authorized Representative. 
 The above listed Services are intended to be utilized by PRIMA to support
several projects including, but not limited to: 
 [ * ] 
 CT agrees to use reasonable efforts to identify percentages of resources dedicated to each type of project (As well as additional future projects) to assist with PRIMA’s cost tracking. This
evaluation shall be provided with CT invoices. 
 In the event that PRIMA requests additional Facilities, personnel, or tasks; or if the volume
of PRIMA’s projects require additional Facilities, personnel, or tasks; or if PRIMA requires specific or special Services that cannot be accomplished with the assigned Facilities, personnel, or task; the Authorized Representatives of the
Parties shall agree to additional Services in writing. 
  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 SCHEDULE 2 
 FEES AND EXPENSES 
 In consideration for the Services provided by CT as detailed in
Schedule 1: 
  

	 	•	 	 PRIMA agrees to pay CT A$77,985 per calendar month (plus GST if required), invoiced monthly in arrears. 

 

	 	•	 	 PRIMA shall reimburse CT for out-of-pocket, third party expenses for consumables, external laboratory testing, capital equipment and validation and
maintenance, at cost plus [ * ] handling fee. Where the unit cost is in excess of [ * ], CT will review the [ * ] handling charge and advise PRIMA of a capped fee which will be related to CT’s effort in managing and processing the purchase. For
the avoidance of doubt, any supplies or equipment reimbursed by PRIMA shall be PRIMA’s property and used exclusively for PRIMA Services. 

  

	 	•	 	 PRIMA shall reimburse CT at cost, without mark-up, for other out-of-pocket, third party expenses, including but not limited to approved travel and
accommodation, regulatory fees, and customs taxes. 

 For agreed additional Services, unless otherwise agreed to by the
Authorized Representatives, PRIMA shall pay CT the following daily rates (plus GST if required): 
  

	 	•	 	 Senior Clinicians [ * ] per day 

  

	 	•	 	 Senior Managers [ * ] per day 

  

	 	•	 	 Senior Scientists [ * ] per day 

  

	 	•	 	 Scientists and Senior Technicians [ * ] per day 

  

	 	•	 	 Laboratory Technicians [ * ] per day 

 Service Fees assume an 8.30am to 5.00pm work day with occasional after-hours or overtime work. If continuous or exceptional after-hours work is required, PRIMA agrees to pay for extra use of Facilities,
including the minimum of two staff required for exceptional after-hours work, at a rate of [ * ]/hour per person. Where time in lieu or rostered days off can be utilised, no additional charges will apply 

PRIMA agrees to pay the following amounts for other potential additional Services that may be requested by PRIMA: 

 

	 	•	 	 Leukapheresis at Peter MacCallum Cancer Center – [ * ] per collection, including disposable apheresis kit set 

 

	 	•	 	 GramStain/BacT alert – as per CMBS rebate, plus a [ * ] loading for trial compliance 

 

	 	•	 	 FACS Sorting – at a rate of [ * ]/hr 

 Service fees are fixed for 12 calendar months from the commencement date. The Authorized Representatives of the Parties agree, in good faith, to review and negotiate any required increases in Service fees
after the first year, and once every year thereafter. 
  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 If the Authorised Representatives are unable to agree on a revised fee within [ * ] of commencing the annual
review then it will be referred for dispute resolution in accordance with Clause 22. If the parties are unable to agree on the revised Services Fee following the completion of dispute resolution, the issue will be referred to an expert nominated by
the President of the Institute of Chartered Accountants for binding determination. 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 SCHEDULE 3 
 PRIMA’S QUALITY POLICY 
 Prima BioMed, Ltd. (“Prima”) is a company of
integrity and high standards, listed on the Australian Stock Exchange for public investment. The Board of Directors of Prima is responsible for the corporate governance of the Company. The Board guides and monitors the business and affairs of the
Company on behalf of the shareholders by whom they are elected and to whom they are accountable. In setting its standards the Company has considered the ASX Corporate Governance Council’s Principles of Good Corporate Governance and Best
Practice. 
 Prima’s mission is to be part of the cutting-edge for the right against cancer by transforming the promise of science and
biotechnology into therapies that have the power to restore health or even save lives of cancer patients. 
 All of Prima’s actions and
business activities are guided by the principles promulgated by the Declaration of Helsinki, as amended. Prima commits to put the well-being and rights of patients before any other consideration. Prima complies with local, national and international
rules and regulations and endeavours to meet and surpass all requirements and expectations related to medical research. 
 In support of
Prima’s mission, Prima guarantees the highest quality and safety standards in the manufacture of its products. The Company has established Codes of Conduct to guide all employees in respect of ethical behaviour expected by Prima. These Codes of
Conduct cover conflicts of interest, confidentiality, fair dealing, protection of assets, compliance with laws and regulations; whistle blowing, security trading and commitments to patients and other stakeholders. 

Staff are made aware of this quality policy and each staff member is responsible for implementing this policy in every area of his or her work.

 Equally, all service providers engaged by Prima are expected to adhere to similar ethical and quality standards. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Cooperation Agreement

 Exhibit 4.5 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 Cooperation Agreement 
 Between 
 Prima BioMed GmbH, 
 Deutscher Platz 5e, 04103 Leipzig 
 -hereinafter referred to as “Prima”-

 And 
 Fraunhofer-Gesellschaft
zur Förderung der angewandten Forschung e. V., 
 Hansastraße 27c, 80686 München 

as legal entity for its 
 Fraunhofer
Institute for Cell Therapy and Immunology (IZI), Leipzig 
 -hereinafter referred to as “IZI” – 

-together hereinafter referred to as “Partners”- 
 for the joint implementation of the project 
 “Pharmacological
Clinical Development of the substance CVacTM” (hereinafter referred to as “Project”) 
 This Project is to
take place in member states of the European Union and non-EU states in Europe. The Project is part of a global multi-center phase 2/3 clinical trial of CVacTM -titled as “CANVAS”- sponsored by Prima BioMed Ltd., Australia. Prima is the legal representative of the
Sponsor according to § 40 Para 1 No. 1 German Drug Act (Arzneimittelgesetz- AMG) and the coordinating Partner for the Project. 

  
 1 

 The Project is partly funded by the Sächsische Aufbaubank (SAB). Co-Funding will be provided through
public funds of the Free State of Saxony and the European Regional Development Fund- ERDF (Europäischer Fonds für regionale Entwicklung- EFRE). 
 Each Party has filed a separate application to the SAB for the allocation of funds to support the allocated work to each Party. 

 

	1.	Subject 

 Subject matter
of this agreement (hereinafter “Agreement” including any of its appendices) shall be the Partners’ co-operation in carrying out the joint Project entitled: 

“Pharmacological clinical development of the substance
CvacTM”. 

Generally, the objectives of this Project are: the clinical implementation of the European part of the clinical trial
(e.g. recruit patients and collect data) and to manufacture the investigational product CvacTM in Leipzig for European (EU and non-EU member states) patients participating on the CvacTM clinical trial. 
 Each Partner shall perform the type and scope of the work described in its respective request for allocation of funds and the framework plan of the Partners (Annex A) as far as any necessary official
authorizations are obtained. Each Partner shall be responsible for the implementation of its work packages to pursue the objectives of the Project. 
  

	2.	Duration 

 The joint Project starts on June 24th, 2011 and has an expected period of performance until [ * ]. 
  

	3.	Rights and Obligations 

  

	3.1	As contacts for all technical-pharmaceutical matters, the parties are to designate the persons named in Annex B (“Responsible Persons”) to this Agreement.
This Annex B shall also contain the names of the Partners’ personnel responsible under the German Drug Act (Arzneimittelgesetz- AMG) as well as the members of each project team. Written notice of any changes and alterations must be given
immediately. Annex B will be adjusted accordingly by the Partners. 

  

	3.2	 IZI will inform Prima about any later restrictions or requirements regarding its manufacturing authorization for CvacTM according to § 13 AMG without undue delay. In addition import
and/or export licenses will be necessary, including, but not limited to the import of Mannan-Fusion Protein (M-FP) from Australia, placebos from Australia as well as Mononuclear Cells (hereinafter “MNC” or “apheresates”) from
procurement centers in third countries, currently Ukraine. Prima shall involve IZI without undue delay if additional clinical trial centers and/or procurement centers in particular in Ukraine or in other third countries

  
 2 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	
are supposed to be included into the Project. IZI shall be entitled to reject cooperation with regard to such trial or procurement centers at its sole discretion for causes, including, but
not limited to political or reputational concerns, security concerns, restrictions out of contracts with third parties, as well as concerns regarding quality of work of the respective center or in case that contractual agreements despite great
efforts cannot be reached. The scope of performance of work package 7 — Manufacture of CvacTM- is depending on the maintenance of the manufacturing authorization and is under the proviso that necessary import and/or export licenses will be granted. 

 

	3.3	 Corresponding to § 9 German Decree for the Manufacture of Medicinal Products and Active Pharmaceutical Ingredients (Arzneimittel- und
Wirkstoffherstellungsverordnung- AMWHV) the Partners have agreed in writing on the division of pharmaceutical responsibilities concerning good manufacturing practice with regard to the manufacturing of the investigational medicinal product
CvacTM by IZI (hereinafter “Quality Agreement”).
The Quality Agreement, as amended from time to time, builds part of this Agreement as Annex C. 

  

	3.4	 IZI will notify Prima without undue delay if it foresees that the amount of CvacTM ordered by Prima in accordance with the Quality Agreement cannot be achieved in due time due to unforeseeable
reasons and/or due to service and/or maintenance of the manufacturing and testing facilities which -in general- causes a shutdown period of about [ * ] working days. In any cases according to this section 3.4 any damage compensation claims of Prima
in case of delay or failure in manufacturing and/or delivery of the amount batches requested shall be precluded hereby. 

  

	4.	Rights of Use and Property Rights 

  

	4.1	 The Partners shall inform each other about the work progress and the research and development results. Inventions, copyright protected works and
know-how generated in the performance of the work under this Project shall be hereinafter referred to as “Protectable Results”. The parties shall exchange interim and final reports in the context of the subject matter of this Agreement.
Furthermore, with respect to work package 7 of the framework plan- Manufacture of CvacTM- the Partners shall inform each other also in accordance with the Quality Agreement. 

  

	4.2	Any results, including Protectable Results generated from Project work allocated to IZI according to Section 1 of this Agreement shall be the exclusive property of
IZI with its exclusive rights of use unless otherwise agreed in this Agreement. 

 It is
expressly acknowledged and agreed to by the Partners that CvacTM manufactured according to this Agreement will be used by Prima for the underlying clinical trial in due consideration of the SAB funding notices as well as the Quality Agreement entered into by the
Partners and with Prima being the exporter of CvacTM
complying with all applicable export control regulations. In addition, IZI will provide Prima with generated Project- specific records concerning manufactured CvacTM including without limitation, regulatory correspondence, 

  
 3 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
batch records, batch- specific manufacturing procedures records, product deviation investigations and reports (hereinafter referred to as “Records”) for use in connection with the
clinical trial, the authorization of CvacTM and any
regulatory interaction with regard to authorities or regulatory agencies. Sentence 1 and 2 of this paragraph are under the proviso of the prior written consent of SAB. Furthermore, it is acknowledged and agreed to by the Partners that any clinical
data resultant from the conduct of the clinical trial (hereinafter referred to as “Clinical data”) shall be the property of Prima and shall be subject to protection as Prima’s Confidential Information as described in section 5.

 IZI shall, to meet its legal and regulatory obligations and as a means to determine and fulfil its ongoing obligations under
this Agreement and in connection with the SAB funding, be allowed to maintain copies of the Records and, notwithstanding section 4.4 below, to use and provide these Records with regard to authorities in connection with the Project. 

 

	4.3	Notwithstanding section 4.2 the Partners agree that if, during the Project, either Partner generates Protectable Results, the generating Partner shall grant the other
Partner a non-exclusive, non-transferable, non-sublicensable, royalty-free right of use to the Protectable Results for the continued duration of the Project and only to the extent such Protectable Results are necessary to implement the Project.

 Upon request, and for further purposes, each Partner shall be granted a non-exclusive, non-transferable,
non-sublicensable license to Protectable Results on fair market conditions which shall be mutually agreed upon prior to the intended use. When assessing the fair market conditions, the necessary contribution of the Partner to the Protectable Result
made in the framework of the cooperation shall be taken into consideration. 
  

	4.4	 Regarding Protectable Results which were generated from IZI- working packages and which are directly and exclusively related to the manufacturing
process or quality of CvacTM, upon Prima’s request,
and in lieu of the right according to section 4.3 paragraph 2, as well as under the proviso of the prior written consent of SAB, Prima shall be granted an exclusive, royalty-bearing right of use to such Protectable Results (and resultant industrial
property rights) for the purpose of future manufacturing and development of CvacTM. A separate agreement will be required and negotiated in good faith. IZI will retain a non- exclusive, royalty-free right of use for purposes of internal and of applied research and development only.
Prima’s request shall be made in writing and addressed to IZI within [ * ] after Prima’s notification of the Protectable Results. 

  

	4.5	 Regarding Protectable Results which were generated from IZI- working packages and which are directly and exclusively related to the manufacturing
process or quality of CvacTM, within the scope of section
4.4, Prima shall assume all obligations of IZI, which can’t be fulfilled by IZI because of Prima’s license (see 4.4), according to IZI’s SAB funding notice as follows: 

In case Prima or IZI do not use the Protectable Results according to section 4.4, Prima shall grant a non-exclusive, irrevocable,
royalty-free and transferable right of use to the SAB including the right to grant sublicenses. In addition Prima shall, upon request and on reasonable conditions, grant a non-exclusive, non transferable and royalty-bearing license to third parties.

  
 4 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	4.6	With regard to section 14 (4) of IZI’s funding notice and section 14 (4) of Prima’s funding notice Prima and IZI acknowledge that SAB might give
consent according to section 4.2 paragraph 2 and section 4.4 of this Agreement only under the proviso of reimbursement of public funds provided to the respective Partner in connection with the Project. In this case Prima shall refund IZI for any
funds to be reimbursed upon request of SAB. Prima acknowledges that its rights according to sections 4.2 paragraph 2 and 4.4 are also under the proviso of refunding of such funds if requested by the SAB. In addition Prima acknowledges that it shall
not within a period of [ * ] from expiration of the Project transfer, sale or license Protectable Results for which it has been granted an exclusive license as specified in section 4.4 to third parties prior to a written consent of SAB and refunding
of funds to be reimbursed by IZI upon request of SAB. 

  

	4.7	The Partners shall agree for each individual case on the treatment of joint inventions (i.e. inventions in which employees of both Partners participate and whose
contributions to the invention cannot be registered separately by each Partner as industrial property rights). During their respective terms, the involved Partners are entitled to use and license such inventions and the industrial property rights
granted to them and without any financial compensation. 

 Regarding joint inventions which
refer exclusively to the manufacturing process or quality of CvacTM sections 4.3, 4.4, 4.5 and 4.6 shall apply. 
 In case of joint copyright
protected works generated within the performance of the Project paragraph 1 and 2 of this section shall apply correspondingly. 
  

	4.8	Prima acknowledges that IZI and its respective professional staff currently possess certain inventions, processes, know-how, trade secrets, methods, approaches,
analyses, improvements, other intellectual properties and other assets including, but not limited to, analytical methods, procedures and techniques, technical expertise and proprietary software, and technical and conceptual expertise in the area of
cell-therapy production, all of which have been developed independently by IZI without the benefit of any information provided by Prima (“IZI- Property”). The parties agree that, notwithstanding any of the foregoing, any IZI- Property
which is used, improved, modified or developed under or during the term of this Agreement as well as any improvement, modification and development thereof shall be and remain the sole and exclusive property of IZI with its exclusive rights of use.

  
 5 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	4.9	If during the performance of the Agreement already existing inventions or industrial property rights of one Partner are required for the implementation of the Project,
a non-exclusive, non-transferable, non-sublicensable and royalty free right of use shall insofar be granted to the other Partner provided that the granting Partner is legally free to do so. Such right of use does not comprise the right to
modification or further development of such inventions or industrial property rights. In the case of copyright protected works and know-how created prior to the Agreement this section shall apply correspondingly. 

 

	4.10	By signing this Agreement Prima grants a non-exclusive, non-transferable, non-sublicensable and royalty free right of use to IZI regarding already existing industrial
property rights (hereinafter “Background IP”) of its own which is required for the implementation of the Project. Likewise Prima acknowledges that it might be necessary for IZI to use Background IP of Prima BioMed Ltd. and other third
parties according to Annex D for the implementation of the Project. Prima represents and warrants that it has obtained a contractual authorization for IZI’s use thereof for the implementation of the Project and Prima ensures and guarantees that
IZI is entitled to use such Background IP free of charge within the Project. With regard to the MNCs as starting materials and other starting materials as well as any data, documents, instructions and further information delivered to IZI by or on
behalf of Prima sentences 1 and 3 shall apply correspondingly. The limitation of Prima’s liability according to Section 6.1 sentence 2 shall not apply with respect to this section 4.10; Prima shall indemnify, defend and hold harmless IZI
from any and all claims made by third parties in case of an infringement of their property rights in connection with the implementation of the Project except in case of intentional failure of IZI. 

 

	4.11	Neither anything contained in this Agreement, nor the delivery of any information or result to a Partner hereto, shall be deemed to grant the receiving Partner any
right or license under any patent or patent application, trademark or trademark application, copyright, trade secrets, or to any know-how, technology or invention of the disclosing Partner except as otherwise stipulated in this Agreement.

  

	4.12	 The Partners acknowledge that any CvacTM vaccines manufactured under this Agreement are intended only for the use as investigational medicinal products for use
in the sponsor’s clinical trial and shall not be used for any other purpose. 

  

	5.	Confidentiality and Publication 

  

	5.1	Each Partner shall keep in confidence for the duration and for a period of [ * ] after the termination of the Project the other Partner’s technical or business
information which was disclosed to it and at that time declared as confidential as well as any information obtained on the occasion of visits at the other party’s facilities irrespective of the information’s designation as confidential,
and shall not disclose or make accessible such information to third parties without the prior written consent of the respective Partner. This obligation shall not apply to any information which is: 

 

	 	-	proven to have been known to the receiving Partner prior to the time of its receipt pursuant to this Agreement; or 

  
 6 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	-	in the public domain at the time of disclosure to the receiving Partner or thereafter enters the public domain without breach of the terms of this Agreement; or

  

	 	-	lawfully acquired by the receiving Partner from an independent source having a bona fide right to disclose the same; or 

 

	 	-	required to be disclosed by law, judicial or administrative process provided that the receiving Partner promptly notifies the disclosing Partner thereof; or

  

	 	-	independently developed by an employee of the receiving Partner who has not had access to any of the Confidential Information of the other Partner.

  

	5.2	Third parties within the meaning of this section 5 shall not include subcontractors of a Partner who have been entrusted with a part of the services in respect to this
Agreement and under the proviso that they are obliged to confidentiality no less than defined herein. 

  

	5.3	Each Partner shall be entitled to publish its research and development results generated under this Agreement. However, publications of Records, publications relating
to joint research and development results, research and development results of the other Partner and/or research and development results for which the other Partner has been granted an exclusive license as specified in section 4.4 shall only be made
after prior consultation with the respective Partner in due time prior to publication. 

 Notwithstanding the
foregoing, the Partners shall be entitled to fulfil their reporting obligations towards SAB without restrictions. 
  

	6.	Liability 

  

	6.1	Unless otherwise agreed in this Agreement as well as with the exception of wilful acts or omissions, neither Partner, its legal representatives, agents and employees
shall be liable for the correctness of the research and development results nor their fitness for purpose nor for information communicated in connection with the Project. Likewise, the Partners, their legal representatives, agents and employees
shall not held be liable for the fact that the rights of use granted by them under this Agreement can be executed without infringement of any third party’s rights. 

Further liability of IZI, its legal representatives, agents and employees shall be limited to intent and gross negligence. Liability of
IZI, its legal representatives, agents and employees for gross negligence shall be limited to the amount of EUR [ * ],-. Liability of IZI, its legal representatives, agents and employees for consequential damages shall be excluded, except in case of
intent. 

  
 7 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	6.2	 Prima shall be liable for all human and other starting materials, including, but not limited to MNCs and M-FP, placebos as well as for all information,
documents, instructions, including, but not limited to, the Batch Record, IMPD, Product Specification File, descriptions of the quality, manufacture, processing, testing, releasing, packaging, storage of CvacTM, technical devices and equipment of Prima (hereinafter
altogether “information”) provided to IZI by or on behalf of Prima according to or in the context of the Quality Agreement or this Project. In addition Prima shall be liable for all information in connection with the Project, in particular
work package 7 of IZI, provided to IZI by or on behalf of Prima BioMed Ltd. prior to the conclusion of this Agreement. 

  

	6.3	 Prima is aware that the investigational medicinal product CvacTM also contains a product liability risk. Prima shall ensure adequate patient safety according to the applicable laws in
the involved countries, including, but not limited to adequate insurance in Germany according to § 40 Para 1 No. 8 German Drug Act and further countries of the European Union according to Art. 3 para. 2 lit. f) directive 2001/20/EC. Prima
shall provide suitable evidence to IZI and submit a copy of the insurance policy or other adequate documents as well as documented evidence of each necessary payment of the insurance premium after signature of this Agreement and [ * ]. Independently
thereof and as IZI is not the pharmaceutical entrepreneur for CvacTM nor the sponsor of the clinical trial, Prima shall indemnify, defend and hold harmless IZI, its qualified person and other employees from any claims made by third parties including, but not limited to,
product liability claims, compensation claims, made against IZI and/or its qualified person and/or other employees for personal injury (including death) or other damages in the context of the manufacturing and/or use of the investigational medicinal
product CvacTM in the clinical trial and/or in connection
with the procurement and/or transport of MNC irrespective of the underlying law and/or in connection with the serological testing as well as the transport of CvacTM, except for liability claims due to failure of IZI by intent. 

 

	7.	Termination 

  

	7.1	Each Partner may terminate its participation in the Project subject to a [ * ] period of notice for good cause only. This applies in particular if further co-operation
has become unacceptable or funding has been reduced significantly in particular if SAB denies payment of further funds after [ * ]. In the event of termination the respective funding authority shall be notified about the withdrawal from the Project.

  

	7.2	In the event of the withdrawal of a Partner 

  

	 	-	its rights of use according to section 4 with the exception of sections 4.3 paragraph 2, 4.4, 4.5, 4.6, 4.7 and 4.8 shall terminate; 

 

	 	-	its obligation according to Section 5 (Confidentiality) and section 6 (Liability) shall remain unaffected; 

  
 8 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 The obligations of the remaining Partner to the withdrawing Partner set forth under section
4, sections 5 and 6 of this Agreement shall be applicable only for research and development results that were attained prior to the receipt of notice. His rights under this Section 7.2 as well as the obligations of the withdrawing Partner set
forth under Sections 4 to 6 shall continue to apply to all research and development results and industrial property rights that are granted to him on the basis of activities which were assumed and/or started in connection with the Project.

  

	7.3	In the event that the Partners mutually agree that the development goal of the Project cannot be attained and that thus the basis for this Agreement ceases to exist the
Partners shall agree on further proceedings, including any rights to already attained research results, and shall conclude a separate agreement, if necessary. 

 

	8.	Concluding provisions 

  

	8.1	FhG/IZI’s obligation to fulfill this Agreement is subject to the provision that the fulfillment is not prevented by any impediments arising out of national and
international foreign trade and customs requirements or any embargoes (or other sanctions), which must especially be observed by FhG/IZI. No claims for damages or similar claims may be asserted against FhG/ IZI for any service not performed for any
one of these reasons either. 

  

	8.2	Ancillary agreements, amendments, additions hereto shall be made in writing. This applies also if the requirement of the written form shall be waived.

  

	8.3	The assignment of rights and/or duties arising from this Agreement and/or the assignment in its entirety shall only be permitted subject to prior written consent of the
other party. 

  

	8.4	If a Partner assigns some of his tasks under this Agreement to a subcontractor, this does not affect its own obligations resulting from this Agreement.

 The subcontracting Partner shall secure that the subcontractor will comply with all obligations resulting from
this Agreement and that the results attained by the subcontractor will be made available to the other Partner according to section 4. In addition the subcontractor shall be contractually bound to comply with pharmaceutical requirements, if
applicable. 
  

	8.5	This Agreement is concluded with the reservation that all Partners are funded by the SAB. The applicable grant conditions shall be supplementary to this Agreement and
shall have priority over the provisions set forth herein. 

  

	8.6	This Agreement shall be governed by the laws of the Federal Republic of Germany. 

  
 9 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	8.7	If any provision of this Agreement is determined to be illegal or in conflict with the applicable law, the validity of the remaining provisions shall not be affected.
The ineffective provision shall be replaced by an effective provision which is economically equivalent. The same shall apply in case of a gap. 

  

	8.8	 This Agreement shall enter into force with the last signature retrospectively as per June 24th, 2011. 

 

			
	München, July 4, 2012	 	Leipzig,  

		
	 Fraunhofer-Gesellschaft zur

Förderung der angewandten
 Forschung
e.V.
	 	Prima BioMed GmbH

  
 

 

  
 10 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 ANNEX A: 

  
 11 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 ANNEX B: 
 Responsible Persons Fraunhofer IZI: 
 Project Team Fraunhofer IZI: 

[ * ] 
 Project Team Prima BioMed GmbH:

 [ * ] 

  
 12 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Annex C: 
 Quality Agreement as amended from time to time 

  
 13 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Annex D: 
 Numbers of Patents: 
 [ * ] 

  
 14 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]